Persistence Market Research Released New Market Report on “Osteoporosis Drugs Market - Global Industry Analysis and Forecast to 2020” in the category "Pharmaceuticals"

New York, NY -- (SBWire) -- 09/19/2014 --Orthopedics market is witnessing high growth rate globally. High incidence of obesity, osteoporosis, osteoarthritis and aging population are some of the key factors driving the market’s growth. Osteoporosis is a condition in which bone mineral density (BMD) decreases, leading to increased risk for fracture. Osteoporosis is a genetic disease and is also termed as “silent disease”, as no symptoms shown in this disease. Osteoporosis drug refers to a medicine that is used to maintain BMD of 2.5 standard deviations below a patient's expected peak bone mass.

BMD decreases with age, therefore aged population is at increased risk for osteoporosis. Based on drug classes, the market has been divided into bisphosphonates, selective estrogen receptor modulators (SERMs), RANK Ligand Inhibitors (denosumab), parathyroid hormone therapy (PTH), calcitonin and others. Osteoporosis is more common in women as compared to men.

Browse the full “Osteoporosis Drugs Market - Global Industry Analysis and Forecast to 2020” report at: http://www.persistencemarketresearch.com/market-research/osteoporosis-drugs-market.asp

Bisphosphonates has the largest market in terms of drug classes in osteoporosis drugs market. North America dominates the global market for osteoporosis drugs due to aging population and increasing prevalence for osteoporosis in the region. Europe followed by the Asia is expected to experience high growth rates in the next few years in global osteoporosis drugs market. This is due to the reason that osteoporosis is a genetic disease and European and Asian population is more susceptible to this disease. Countries, such as Brazil, Russia, China and India are expected to be the fastest growing osteoporosis drugs markets. Some of the key driving forces for osteoporosis drugs market in emerging countries are large pool of patients and rising standards of healthcare in these areas.

Rising prevalence of osteoporosis among female population and aging population are driving the global osteoporosis drugs market. According to International Osteoporosis Foundation census, globally, in 2013, more than 200 million people were affected by osteoporosis. Out of which 80% was female population. Post-menopausal women are more susceptible to this disease. This is due to decrease in estrogen level in the body after these hormonal changes, which is linked with decline in BMD. In addition, introduction of new drugs in the market, with greater efficacy and less side effects drive the market for osteoporosis drugs. Increasing awareness and sedentary lifestyle also drive the global osteoporosis drugs market. However, strict regulations and investigations in clinical trials by regulatory authorities impede global osteoporosis drugs market. In addition, high cost involved and patent expiries of drugs restrain the osteoporosis drugs market.

Request For Complete Table of Content:
http://www.persistencemarketresearch.com/toc/2983

With increase in awareness, diagnosis and treatment for osteoporosis, demand for new drugs that promote bone building is expected to increase. This is expected to offer a good opportunity for osteoporosis drugs market. In addition, increasing research and development worldwide for innovation of better drugs is expected to drive osteoporosis drugs market. Companies focussing on emerging markets for their geographical expansion are some of the recent trends that have been observed in the osteoporosis drugs market. Some of the key players operating in global osteoporosis drugs market are Amgen Inc., Eli Lilly & Co., Merck & Co. Inc. and Novartis AG. Other significant players in the global market for osteoporosis drugs include Actavis plc, F. Hoffmann-La Roche Ltd., Novo Nordisk A/S, Pfizer, Inc. and Teva Pharmaceutical Industries Ltd.

Key points covered in the report:

1. Report segments the market on the basis of types, application, products, technology, etc (as applicable)

2. The report covers geographic segmentation

North America
Europe
Asia
RoW

3. The report provides the market size and forecast for the different segments and geographies for the period of 2010 to 2020

4. The report provides company profiles of some of the leading companies operating in the market

5. The report also provides porters five forces analysis of the market.

Browse the full “All Upcoming Persistence Market's ” report at
http://www.persistencemarketresearch.com/forthcoming-reports.asp

About Persistence Market Research
Persistence Market Research (PMR) is a U.S.-based full-service market intelligence firm specializing in syndicated research, custom research, and consulting services. PMR boasts market research expertise across the Healthcare, Chemicals and Materials, Technology and Media, Energy and Mining, Food and Beverages, Semiconductor and Electronics, Consumer Goods, and Shipping and Transportation industries. The company draws from its multi-disciplinary capabilities and high-pedigree team of analysts to share data that precisely corresponds to clients’ business needs.

PMR stands committed to bringing more accuracy and speed to clients’ business decisions. From ready-to-purchase market research reports to customized research solutions, PMR’s engagement models are highly flexible without compromising on its deep-seated research values.

Contact Us:

Addie Thomes
305 Broadway
7th Floor
New York City, NY 10007
United States
Phone: 646-568-7751
USA/Canada Toll Free Number
800-961-0353
E-mail: Sales@persistencemarketresearch.com
Web : http://www.persistencemarketresearch.com